Innovative Nanoparticles Enhance Precision in mRNA and siRNA Therapies

Researchers develop siloxane and NMR-guided lipid nanoparticles to improve targeted delivery and efficacy of gene therapies.

University of Pennsylvania engineers have developed siloxane-incorporated lipid nanoparticles (SiLNPs) that can target specific tissues, including the liver, lungs, and spleen.
The inclusion of siloxane composites in lipid nanoparticles enhances stability and reduces toxicity, leading to a sixfold improvement in mRNA delivery compared to existing methods.
NMR-based studies by Chiba University researchers reveal that the method of mixing siRNA with lipid nanoparticles is crucial for achieving uniform siRNA distribution and enhanced gene-silencing effects.
Pre-mixed siRNA-loaded LNPs exhibit superior gene-silencing efficiency due to a more uniform distribution and tightly associated ionizable lipids forming a stacked bilayer structure.
These advancements in nanoparticle design hold promise for applications in personalized medicine, including protein replacement therapies, regenerative medicine, and CRISPR-Cas-based gene editing.